HOME >> MEDICINE >> NEWS
Experts to address use of patient-reported outcomes in clinical trials at joint Mayo-FDA forum

Dozens of medical research experts will assemble Feb. 23-25, 2006, in Chantilly, Va., to discuss how patient-reported outcomes (PROs) should be developed, validated, interpreted and used in clinical trials. This symposium, jointly sponsored by Mayo Clinic and the U.S. Food and Drug Administration (FDA), is a forum for discussion and feedback regarding the soon-to-be-released FDA draft guidance for industry on using PRO measures to support medical product labeling claims. The draft guidance will be published in the Federal Register with an invitation for public comment.

"Exactly how we incorporate patient-reported outcomes into cancer research has been murky for a long time. It is a great opportunity to bring clarity and consensus to the issue," says Jan Buckner, M.D., Mayo Clinic medical oncologist and chair of the North Central Cancer Treatment Group (NCCTG). The group specializes in researching methods of treating and preventing cancer, as well as methods to alleviate the side effects of cancer and cancer treatments. "Clinicians and researchers around the world are going to be able to use the information presented at this symposium as a guide for how and when to use patient-reported outcomes. It's really a step forward for all of us."

Five writing teams composed of experts in PRO research will present papers on the major themes covered in the draft guidance: conceptual issues; PRO instrument selection; PRO instrument development issues; validation of PROs; and analysis, interpretation and reporting results based on PROs. Each document will include recommendations on the most appropriate methods of how PROs should be incorporated into clinical trials, and will advocate additional research needed to overcome limitations currently faced in the application of PROs. Attendees will have the opportunity to discuss and comment on these papers as well as the FDA's draft guidance.

FDA's experts in PRO measurement in clinical trials also wil
'"/>

Contact: Elizabeth Zimmermann
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
25-Jan-2006


Page: 1 2

Related medicine news :

1. Experts predict Tamiflu could halve the pandemic influenza death toll versus no intervention
2. Experts call for urgent research into anti-epileptic drugs given to children
3. Experts debate role of stenting, bypass surgery in left main coronary artery disease
4. Medicalize me: Experts look at how our perceptions of illness are shaped
5. Experts urge strongest isolation for new drug-resistant tuberculosis cases appearing in South Africa
6. Experts add to growing warnings about asthma drug
7. Experts review current and future approaches to dementia diagnosis
8. Experts present strategies to address adolescent violence and bullying
9. Experts call for balance in addressing under treated pain and drug abuse
10. Experts question prevalent stereotypes about autism
11. Experts call for re-focussing of COPD management to reduce hospital admissions and mortality

Post Your Comments:
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... officials on Monday officially tightened guidelines for health workers treating ... exposure and use of a respirator at all times. ... issue the tougher rules after two Dallas nurses contracted Ebola ... United States, Liberian national Thomas Eric Duncan. Nina Pham is ...
(Date:10/20/2014)... The newly updated Worldwide Medical Market ... of facts, figures and forecasts on the global medical ... forecast categories the Worldwide Medical Market Forecasts to ... views on the worldwide medical market to reveal key ... you data for 2010-2019, covering each country market individually, ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is ... repair a damaged mitral valve as the heart continues ... by Abbott Vascular , is designed to treat ... in which the heart’s mitral valve leaflets fail to ... heart’s left ventricle into the left atrium. The heart ...
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
(Date:10/20/2014)... October 20, 2014 T.E.N., a ... firm, announced today that William H. Murray, renowned ... 2014 ISE® Luminary Leadership Award winner. Presented annually, ... of an outstanding leader and industry practitioner for ... in advancing the information security industry. , Formerly ...
Breaking Medicine News(10 mins):Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
(Date:10/20/2014)...  ResMed (NYSE: RMD ) today ... program, a comprehensive suite of software and service ... health care providers. ResMed Data ... information. It integrates valuable sleep and respiratory treatment ... platforms with customers, in-house or third-party electronic health ...
(Date:10/20/2014)...   BioNano Genomics announced today achievement of a ... human data at 30X depth, sufficient for a genome map, ... was established and demonstrated for the IrysChip TM V2, ... and will be rolled out to BioNano,s collaborators and ... this advancement at the American Society for Human Genetics ...
(Date:10/20/2014)... , Oct. 20, 2014   Taiho Oncology, ... Ltd. ( Japan ), announced that ... Fast Track designation for TAS-102 (nonproprietary names: trifluridine ... under investigation for the treatment of refractory metastatic ... initiated a rolling NDA submission to the FDA. ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
Cached News: